| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.tridentlifeline.com | |
| Market Cap | 183.99 Cr. | |
| Enterprise Value(EV) | 190.18 Cr. | 2024-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 5.52 | Trailing Twelve Months Ending 2024-03 |
| Price-Earning Ratio (PE) | 29.00 | Trailing Twelve Months Ending 2024-03 |
| Industry PE | 42.28 | Trailing Twelve Months Ending 2024-03 |
| Book Value / Share | 40.60 | Trailing Twelve Months Ending 2024-03 |
| Price to Book Value | 3.94 | Calculated using Price: 160.00 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 1.15 Cr. | 11,499,200 Shares |
| FaceValue | 10 | |
| About Trident Lifeline Ltd. | ||
| The company is engaged in the manufacturing and marketing of quality finished dosages. It is one of the fastest growing pharmaceutical companies in the SME segment providing unprecedented quality of healthcare products. It deals in Capsules, Tablets, Liquid Ointment, Gel, Ice Gel, Mouthwash, Paste, Solution, Suspension, Drypowders and Toothpaste. | ||
| 1 Day |
|
+1.27% |
| 1 Week |
|
-3.03% |
| 1 Month |
|
+3.56% |
| 3 Month |
|
-12.62% |
| 6 Month |
|
-16.67% |
| 1 Year |
|
+12.68% |
| 2 Year |
|
|
| 5 Year |
|
|
| 10 Year |
|
| 2 years | 2022-03 | 2023-03 | |
| Return on Equity (%) | 83.23 | 24.05 | |
| Return on Capital Employed (%) | 43.21 | 24.32 | |
| Return on Assets (%) | 30.72 | 16.83 |
| Particulars | 3 years | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2024-03* Rs. Cr. |
| Shh. Funds | 5 | 46 | 52 | |
| Non Curr. Liab. | 0 | 2 | 13 | |
| Curr. Liab. | 8 | 11 | 20 | |
| Minority Int. | 1 | |||
| Equity & Liab. | 13 | 59 | 87 | |
| Non Curr. Assets | 2 | 9 | 35 | |
| Curr. Assets | 11 | 49 | 52 | |
| Misc. Exp. not W/O | 0 | 0 | ||
| Total Assets | 13 | 59 | 87 |
| Particulars | 2 years | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Net Sales | 22 | 32 | |
| Other Income | 1 | 1 | |
| Total Income | 22 | 33 | |
| Total Expenditure | -19 | -25 | |
| PBIDT | 3 | 7 | |
| Interest | 0 | 0 | |
| Depreciation | 0 | 0 | |
| Taxation | 1 | -1 | |
| Exceptional Items | |||
| PAT | 4 | 6 | |
| Minority Interest | |||
| Share Associate | |||
| Other Related Items | |||
| Consolidated Net Profit | 4 | 6 | |
| Adjusted EPS | 5 | 5 |
| Particulars | 2 years | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | -17 | |
| Cash Fr. Inv. | 0 | -7 | |
| Cash Fr. Finan. | 1 | 38 | |
| Net Change | 0 | 14 | |
| Cash & Cash Eqvt | 0 | 14 |
|
Thu, 02 May 2024
Intimation Of Change Of Holding In TLL PARENTERALS LIMITED (CIN: U21001GJ2023PLC146963)(Subsidiary Company). Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) we wish to inform you that TLL PARENTERALS LIMITED (TPL) has ceased to be a subsidiary of the Company w.e.f. today due to reduction in holding from 51.00% to 0.51% upon allotment of equity shares pursuant to right issue to the other existing member of TLL PARENTERALS LIMITED who have accepted the offer. |
|
Wed, 01 May 2024
Announcement under Regulation 30 (LODR)-Investor Presentation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith Earnings Presentation for the half year and year ended 31st March 2024 (H2FY24). |
|
Wed, 01 May 2024
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer With reference to the above captioned subject and pursuant to Regulation 30 of the SEBI (LODR) Regulations 2015 this is to inform you that Mr. Jiteshkumar R Varkal (Membership No. ACS 31727) has tendered his resignation from the post of Company Secretary & Compliance Officer of the Company with effect from 30th May 2024. We request you to please take the same on record. |
| Fri, 03 May 2024 |
High Delivery Percentage
|
Opening at High
|
Opening at Low
|
Closing Below Previous Low
|
High Decrease in 3 Months
|
